Education
About Us
Working with TipRanks
Follow Us
Q32 Bio (QTTB)
NASDAQ:QTTB
QTTB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.38 - $53.79
Previous CloseN/A
Volume113.57K
Average Volume (3M)170.33K
Market Cap
$23.30M
Enterprise Value-$17.16M
Total Cash (Recent Filing)$46.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.21
Next Earnings
May 08, 2025EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-10.37
Shares Outstanding12,197,615
10 Day Avg. Volume168,545
30 Day Avg. Volume170,329
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)21.84
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-29.69
Enterprise Value/Ebitda0.39
Forecast
1Y Price Target
$13.00Price Target Upside584.21% Upside
Rating ConsensusHold
Number of Analyst Covering4
---
Q32 Bio News
See All QTTB News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsAll patients who completed Part A treatment maintained hair after 36 weeks and beyond, with some achieving additional hair growth post-treatment.
Corporate StrategyThe restructuring decision shows confidence in focusing on bempikibart development for alopecia areata patients.
Patient FeedbackBempi is well tolerated and patients are satisfied with outcomes, indicating potential positive feedback from ongoing studies.
Bears Say
Financial PerformanceQTTB is down -40% YTD as there remains investor cautiousness around bempi's activity in alopecia areata.
Market ComparisonComparison with Pfizer's JAK inhibitor shows a significantly lower response rate for bempikibart, affecting its valuation.
Stock ValuationThe data is not supportive of bempikibart valuation beyond current assumptions, with a 15% probability of achieving peak sales.
---
Ownership Overview
2.72% Insiders
6.84% Mutual Funds
<0.01% Other Institutional Investors
85.13% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
QTTB FAQ
What was Q32 Bio’s price range in the past 12 months?
Q32 Bio lowest stock price was $1.38 and its highest was $53.79 in the past 12 months.
What is Q32 Bio’s market cap?
Q32 Bio’s market cap is $23.30M.
When is Q32 Bio’s upcoming earnings report date?
Q32 Bio’s upcoming earnings report date is May 08, 2025 which is in 14 days.
How were Q32 Bio’s earnings last quarter?
Q32 Bio released its earnings results on Mar 11, 2025. The company reported -$1.16 earnings per share for the quarter, beating the consensus estimate of -$1.53 by $0.37.
Is Q32 Bio overvalued?
According to Wall Street analysts Q32 Bio’s price is currently Undervalued.
Does Q32 Bio pay dividends?
Q32 Bio does not currently pay dividends.
What is Q32 Bio’s EPS estimate?
Q32 Bio’s EPS estimate is -1.23.
How many shares outstanding does Q32 Bio have?
Q32 Bio has 12,197,615 shares outstanding.
What happened to Q32 Bio’s price movement after its last earnings report?
Q32 Bio reported an EPS of -$1.16 in its last earnings report, beating expectations of -$1.53. Following the earnings report the stock price went down -7.767%.
Which hedge fund is a major shareholder of Q32 Bio?
Currently, no hedge funds are holding shares in QTTB
---
Q32 Bio Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$13.00 (584.21% Upside)
$13.00 (584.21% Upside)
Blogger Sentiment
Bullish
QTTB Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 162.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 6.5%
Last 30 Days ▼ 6.5%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.30%
12-Months-Change
Fundamentals
Return on Equity
-121.36%
Trailing 12-Months
Asset Growth
-69.84%
Trailing 12-Months
Company Description
Q32 Bio
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.
---
QTTB Stock 12 Month Forecast
Average Price Target
$13.00
▲(584.21% Upside)
Technical Analysis
Tempest Therapeutics
―
Chemomab Therapeutics
―
Annovis Bio
―
Passage Bio
―
Cognition Therapeutics
―
Best Analysts Covering QTTB
1 Year
1 Year Success Rate
1/5 ratings generated profit
1 Year Average Return
-68.32%
reiterated a buy rating last month
Copying Jay Olson's trades and holding each position for 1 Year would result in 20.00% of your transactions generating a profit, with an average return of -68.32% per trade.
---